WeightWatchers Customers Can Now Access Wegovy at a Lower Price Through New Deal with Novo Nordisk
WeightWatchers subscribers in the US will soon have easier and more affordable access to the popular weight-loss drug Wegovy, thanks to a fresh partnership between the diet brand and Danish pharmaceutical giant Novo Nordisk.
This new move comes shortly after Novo Nordisk ended a similar deal with another company, Hims & Hers Health Inc.
What’s New in the Deal?
Starting 1 July 2025, WeightWatchers members will be able to get prescriptions for Wegovy through CenterWell Pharmacy — a trusted pharmacy partner.
Key Highlights of the Offer:
Discounted price of $299 for self-pay patients beginning treatment with Wegovy.
Patients who previously used a $199 promotional offer can also continue at the $299 refill rate.
This pricing is part of a limited-time introductory programme, aimed at making the drug more accessible during its rollout.
Why Wegovy? And Why Now?
Wegovy, made by Novo Nordisk, is one of the most sought-after weight-loss medications in the US. It works by mimicking a natural hormone that controls appetite and helps with long-term weight management.
With the growing demand for effective obesity treatments, pharmaceutical companies are rushing to secure partnerships and attract customers. This new agreement between Novo and WeightWatchers is a clear attempt to regain market share.
Partnership Shifts: Novo Nordisk Ends Deal with Hims
Interestingly, this WeightWatchers deal comes just days after Novo Nordisk cancelled its agreement with Hims & Hers Health Inc.
Why the Split?
Hims allegedly continued promoting a generic version of Wegovy.
This violated their agreement with Novo Nordisk, which aimed to promote the official brand-name drug.
WeightWatchers’ Struggles and Comeback Strategy
Once a leading name in dieting, WeightWatchers has faced serious challenges in recent years. Despite being endorsed by celebrities, the brand struggled to keep up with the booming popularity of prescription weight-loss drugs like Wegovy and Zepbound (by Eli Lilly).
Key Updates:
Filed for bankruptcy last month amid financial difficulties.
Shifted its strategy to include prescription weight-loss medication as a core offering.
Faced hurdles in attracting new patients, despite attempting to sell both original and copycat versions of weight-loss drugs.
Current User Base: WeightWatchers vs Hims
Despite the setbacks, WeightWatchers still boasts a stronger subscriber base compared to Hims.
3.4 million subscribers as of May 2025 (according to company filings).
Hims had around 2.4 million subscribers in the same period.
WeightWatchers offers fewer healthcare products, but its brand recognition and loyal user base give it an edge.
What Does This Mean for Consumers?
For many Americans struggling with obesity or managing weight, this new partnership means:
Easier access to Wegovy for WeightWatchers members.
More affordable treatment options, especially for those without insurance.
A sign that mainstream wellness brands are evolving, embracing medical solutions over traditional diet plans alone.
Sources:
Bloomberg – for original reporting on Novo Nordisk’s announcement.
Reuters – updates on WeightWatchers’ bankruptcy filing.
Novo Nordisk official website – for details on Wegovy and corporate news.
In Summary:
Novo Nordisk’s new deal with WeightWatchers could reshape the way Americans access obesity medication. As competition heats up between Wegovy and Zepbound, patients may benefit from better pricing and more options — especially as trusted wellness brands like WeightWatchers join forces with pharmaceutical companies.
Let’s see if this move helps both companies bounce back and gives more people the support they need in their health journey.